Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Cell Chem Biol. 2022 Feb 17;29(2):171-173. doi: 10.1016/j.chembiol.2022.02.002.

Abstract

In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Phthalazines / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Phthalazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • talazoparib